Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 1
Submit an article Journal homepage
158
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

MiR-181a enhances drug sensitivity of mixed lineage leukemia-rearranged acute myeloid leukemia by increasing poly(ADP-ribose) polymerase1 acetylation

Di Zhoua Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, People’s Republic of ChinaView further author information
,
Peipei Xua Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, People’s Republic of ChinaView further author information
,
Xuan Zhoua Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, People’s Republic of ChinaView further author information
,
Zhenyu Diaob Department of Reproductive Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, People’s Republic of ChinaView further author information
,
Jian Ouyanga Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, People’s Republic of ChinaView further author information
,
Guijun Yanb Department of Reproductive Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, People’s Republic of ChinaView further author information
&
Bing Chena Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 136-146 | Received 01 Feb 2020, Accepted 07 Sep 2020, Published online: 30 Sep 2020

References

  • Meyer C, Hofmann J, Burmeister T, et al. The MLL recombinome of acute leukemias in 2013. Leukemia. 2013;27(11):2165–2176.
  • de Boer J, Walf-Vorderwülbecke V, Williams O. In focus: MLL-rearranged leukemia. Leukemia. 2013;27(6):1224–1228.
  • McMahon KA, Hiew SY-L, Hadjur S, et al. Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal. Cell Stem Cell. 2007;1(3):338–345.
  • Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7(11):823–833.
  • Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002;30(1):41–47.
  • Slany RK. The molecular biology of mixed lineage leukemia. Haematologica. 2009;94(7):984–993.
  • Andersson AK, Ma J, Wang J, et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet. 2015;47(4):330–337.
  • 2017. ClinicalTrials.gov. Identifier: NCT03151408.
  • Malumbres M. miRNAs and cancer: an epigenetics view. Mol Aspects Med. 2013;34(4):863–874.
  • Zhang M, Zhang Q, Hu Y, et al. miR-181a increases FoxO1 acetylation and promotes granulosa cell apoptosis via SIRT1 downregulation. Cell Death Dis. 2017;8(10):e3088.
  • Zhou B, Li C, Qi W, et al. Downregulation of miR-181a upregulates sirtuin-1 (SIRT1) and improves hepatic insulin sensitivity. Diabetologia. 2012;55(7):2032–2043.
  • Zhao J, Gong AY, Zhou R, et al. Downregulation of PCAF by miR-181a/b provides feedback regulation to TNF-α-induced transcription of proinflammatory genes in liver epithelial cells. J Immunol. 2012;188(3):1266–1274.
  • Marcucci G, Radmacher MD, Maharry K, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1919–1928.
  • Schwind S, Maharry K, Radmacher MD, et al. Prognostic significance of expression of a single MicroRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2010;28(36):5257–5264.
  • NCCN Guidelines Version 1. 2017. Panel members acute myeloid leukemia. National Comprehensive Cancer Network 2017; [cited 2017 Jun 20]. Available from: https://www.nccn.org/professionals/physician_gls/
  • Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588–5599.
  • Boehrer S, Ades L, Tajeddine N, et al. Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome. Oncogene. 2009;28(22):2205–2218.
  • Kefala M, Papageorgiou SG, Kontos CK, et al. Increased expression of phosphorylated NBS1, a key molecule of the DNA damage response machinery, is an adverse prognostic factor in patients with de novo myelodysplastic syndromes. Leuk Res. 2013;37(11):1576–1582.
  • Cavelier C, Didier C, Prade N, et al. Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy. Cancer Res. 2009;69(22):8652–8661.
  • Yelamos J, Farres J, Llacuna L, et al. PARP-1 and PARP-2: new players in tumour development. Am J Cancer Res. 2011;1(3):328–346.
  • Huang JY, Chen WH, Chang YL, et al. Modulation of nucleosome-binding activity of FACT by poly(ADP-ribosyl)ation. Nucleic Acids Res. 2006;34(8):2398–2407.
  • Esposito MT, Zhao L, Fung TK, et al. Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors. Nat Med. 2015;21(12):1481–1490.
  • Silvia Maifrede EM, Nieborowska-Skorska M, Di Marcantonio D, et al. MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs. Blood Adv. 2017;1(19):1467–1472.
  • Francica P, Rottenberg S. Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response. Genome Med. 2018;10(1):101.
  • Gogola E, Duarte AA, de Ruiter JR, et al. Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality. Cancer Cell. 2018;33(6):1078–1093.
  • Yamaguchi H, Woods NT, Piluso LG, et al. p53 acetylation is crucial for its transcription-independent proapoptotic functions. J Biol Chem. 2009;284(17):11171–11183.
  • Robert C, Nagaria PK, Pawar N, et al. Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin. Leuk Res. 2016;45:14–23.
  • Su R, Lin HS, Zhang XH, et al. MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets. Oncogene. 2015;34(25):3226–3239.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.